• Celerion Newsletter
Belfast - Center of Excellence for Respiratory

Celerion

committed to service excellence

Primary Navigation for Celerion

  • Home
  • About Celerion
    • Why Celerion?
    • Mission, Vision and Credo
    • Management Team
    • Who We Work With
    • Locations
    • Environmental Sustainability
  • Applied Translational Medicine
    • Key Elements of Success
  • Services
    • Global Clinical Research
      • AAHRPP Accreditation
      • Phase I and lla Studies
      • In-hospital Beds
      • Study Experience
      • Belfast – Center of Excellence for Respiratory
      • Early Cardiac Services
      • Hybrid Phase I/ECG Core Lab
      • ADME/Mass Balance
      • Microtracer Studies
      • USP <797> Clean Room
      • ClinQuick® Electronic Data Acquisition
      • Recruitment
    • Clinical Pharmacology Sciences
      • Modeling and Simulation
      • Study Design and Protocol Development
      • Data Programming
      • Biostatistics
      • Pharmacokinetics/Pharmacodynamics (PK/PD)
      • Medical Writing and Reporting
      • Streamlined Data Flow Process
    • Global Bioanalytical Services
      • Small Molecule
      • Large Molecule
      • Electronic Laboratory Notebook System
      • ADME/Mass Balance
    • Drug Development Services
      • Biopharmaceutical Development
      • Program and Project Management
      • Regulatory Affairs
  • Celerion Europe
    • Global Clinical Research
    • Clinical Pharmacology Sciences
    • Global Bioanalytical Services
    • Management Team
  • The Biosimilars Alliance
    • The Biosimilars Alliance – Overview
    • The Biosimilars Alliance – Benefits
  • Case Studies
    • Global Clinical Research
      • Responding to an Unexpectedly High Drop Rate
      • Mass Balance Study
      • Semen Clinical Trials
    • Clinical Pharmacology Sciences
      • Partnering with Biotechnology Companies
      • Partnering with Large Pharmaceutical Companies
      • Protocol Study Design and Development for Generic Studies
      • Difficult to Recruit Population
      • Consistent Database Structure for Programs of Studies
    • Global Bioanalytical Services
      • Improved Desmopressin Analysis of Clinical Samples
      • Optimized LC-MS/MS Method for New Observed Metabolite
      • Bioanalytical Support of Oncology Studies
      • High Throughput Bioanalytical Analysis
      • Partnering with Biotechnology Companies
      • Partnering with Pharmaceutical Companies
      • Development of an LC-MS/MS Peptide Method
    • Drug Development Services
      • Support of CMC to IND for Novel First-in-Class Small Molecule Drugs
      • Rapid Proof-of-Concept for Novel Drug Treatment for Rare Metabolic Disease
      • Proof-of-Concept Efficacy Clinical Study
      • European Biotechnology Company Seeking First-in-Human U.S. Clinical Study
      • Asian Biotechnology Company with CNS Compound
  • White Papers
  • Other Resources
  • News & Events
    • Press Room
    • Conferences
    • Symposia
    • Webinars
  • Participate in a Study
  • Careers
    • Message from the CEO
    • Culture
  • Spring 2013 Newsletter
  • Fall 2012 Newsletter
  • Spring 2012 Newsletter

Services > Clinical Pharmacology Sciences

Streamlined Data Flow Process

Streamlined Data Flow Process Diagram

Celerion's streamlined data-flow process maintains consistency with industry-leading CDISC standards from data collection through data submission.

Data Capture
ClinQuick®, our proprietary electronic data-acquisition system, provides consistency of clinical operations across our sites, ensuring accurate, high-quality data and reducing time to database lock.

Data Output
Celerion utilizes our in-house CDASH-compliant data-acquisition SAS® database format and associated electronic PDF format CRFs to set initial expectations, fully scope the project and standardize accepted data formats, resulting in time savings on the back-end. The submission database content/structure is usable throughout the drug-development lifecycle of a compound, reducing costs and eliminating rework.

Data Migration
Celerion expedites the conversion of clinical study data from CDASH to CDISC while maintaining compliance with FDA and other regulatory agencies. Our extensive services include biostatistics – detailed statistical analysis plans, and tables, figures and listings (TFLs) in addition to PK/PD analysis and interpretation.

Data Submission
Celerion is one of the leading CROs for complete data reporting, thereby saving sponsors' time and money on overall drug-development timelines. The structure of the ICH E3 Clinical Study Report is compliant with the eCTD and is delivered as a fully electronic PDF format standard deliverable (vs. paper) to assist clients in their submission process. The addition of SAS Drug Development to our services portfolio enables Celerion to deliver submission-ready data in an eCTD-compliant format while expediting delivery of items 11 and 12.

See also...

Presentation: A Streamlined Data Capture and Exchange Partnership that Delivers Faster Decisions

Award Winning Scientific Poster: Using PROC TEMPLATE to Convert SAS Data to Define.xml

For more information contact us

Footer Naviation

  • About
  • Locations
  • Careers
  • Request a Proposal
  • Contact
  • Privacy Policy
© 2013 Celerion